Cell Procurement & Processing
Cell Procurement & Processing
批准号:
10472481
负责人:
DEREK L STIREWALT
金额:
$22.96万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-08-01 至 2026-07-31
关键词:
AwardAwarenessBioinformaticsBiologyCellsCharacteristicsClinicalCommunitiesDataData Management ResourcesDiseaseDocumentationEducational workshopEnsureEquipment and supply inventoriesExplosionFeedbackFundingFunding MechanismsHematologyHematopoiesisHematopoieticHematopoietic stem cellsIndividualInfrastructureInstitutionInvestigationLiteratureMeasuresModelingNatureNon-MalignantPriceProductionQuality ControlRecording of previous eventsReproducibilityResearchResearch PersonnelResourcesRetrievalSpecimenStandardizationStem cell transplantSurveysTechniquesTechnologyTestingTimeWorkbasecostexperiencefollow-uphigh standardimprovedinnovationmeetingsmembermultidimensional datanew technologynovelnovel strategiespostersprecursor cellprogramsquality assuranceranpirnasesatisfactionsearchable databaseskillssoftware developmentsoftware systemssuccesstooluser-friendlyvirtualweb site
中文摘要
项目概要/摘要-细胞采购和处理核心
Cell采购和处理(Cell P&P)核心的目的和目标仍然是促进
了解造血和非恶性疾病通过高质量的分布,
血液学研究界的造血产品。为了满足这一需求,
Cell P&P Core于1999年在最初的CCEH P30下成立。在近20年的历史中,
Cell P&P Core已被公认为正常造血细胞产品的国家资源,
69家机构的171名研究人员证明,
前一个奖项。此外,对核心方案资源的利用继续增加,
这些研究促进了我们对控制正常造血的生物学的理解,
非恶性疾病作为拟议奖励的一部分,细胞P&P核心将利用其专业知识,
基础设施和经验,以增加生产和利用高质量的产品,以推进
血液学研究领域,同时保持产品质量的当前高标准,如
研究战略。因此,Cell P&P Core提出以下建议:
具体目标1。扩大用户数量为最高的造血细胞富集产品
质量和一致性,以促进血液学研究。我们提出了三种新的方法来增加
用户号码。1)Cell P&P核心开发了一个新的用户满意度和需求计划,
反馈和识别新用户。2)核心将开发针对现有和新的虚拟研讨会
用户. 3)核心将开发一种新的资助机制,称为细胞P&P新研究者奖,
以大幅降低的价格提供资源。具体目标2。开发用户友好、综合和
造血标本综合数据管理系统(DMS)。拟议的DMS将
结合实时评估,以跟踪和检索捐助者特征、分析前变量
SOP、库存、质量控制、质量保证和样本分发,这将有两个主要的
有益效果。1)核心将能够更有效地为用户提供有关的基本变量,
他们的研究。2)核心将能够更迅速和全面地评估质量措施,
评价影响产品均匀性的潜在变量。具体目标3。开发新的创新
用户导向的产品,以促进血液学研究。鉴于新技术的爆炸式发展,
检查造血细胞,这仍然是一个挑战,研究人员获得的技能,利用
这些技术。通过将Cell P&P和Tool Cores的专业知识相结合,我们将能够高效地
开发和提供用户导向的产品给那些研究者,否则他们可能无法开发
这些产品在他们的实验室里。通过这些成果,我们将扩大这些领域的研究潜力,
研究人员,并提供了一个机制,以增加血液学研究。
英文摘要
PROJECT SUMMARY/ABSTRACT - Cell Procurement and Processing Core
The purpose and objective of the Cell Procurement and Processing (Cell P&P) Core remains to advance the
understanding of hematopoiesis and nonmalignant disorders through the distribution of high-quality
hematopoietic products to the hematology research community. To meet this need, the early precursors of
Cell P&P Core was first established in 1999 under the original CCEH P30. Over the almost 20-year history,
The Cell P&P Core has become recognized as a national resource for normal hematopoietic cell products, as
evidenced by the 171 investigators at 69 institutions who have received hematopoietic products during the
previous award period. Moreover, utilization of resources from the Core have continued to grow and facilitate
investigations that have advanced our understanding of the biology governing normal hematopoiesis and
nonmalignant disorders. As part of the proposed award, the Cell P&P Core will leverage its expertise,
infrastructure, and experiences to increase production and utilization of the high-quality products to advance the
field of hematology research, while maintaining the current high standards for product quality as detailed in the
Research Strategy. Therefore, the Cell P&P Core proposes the following:
Specific Aim 1. Expand the number of users for enriched hematopoietic cell products of the highest
quality and uniformity to facilitate hematology research. We propose three new approaches to increase
user numbers. 1) The Cell P&P Core develop a novel User Satisfaction and Needs Program to provide
feedback and identify new users. 2) The Core will develop Virtual Workshops targeting existing and new
users. 3) The Core will develop a novel funding mechanism called Cell P&P New Investigator Award that
provide resources at significantly reduced prices. Specific Aim 2. Develop user-friendly, integrative and
comprehensive Data Management System (DMS) for hematopoietic specimens. The proposed DMS will
incorporate real-time assessment for tracking and retrieval of donor characteristic, pre-analytic variables,
SOPs, inventory, quality controls, quality assurances, and specimen distribution, which will have two major
beneficial effects. 1) The Core will be able to more efficiently provide users with the essential variables related
to their research. 2) The Core will be able to more rapidly and comprehensively assess quality measures and
evaluate potential variables impacting product uniformity. Specific Aim 3. Develop new and innovative
user-directed products to facilitate hematology research. Given the explosion of new technologies to
examine hematopoietic cells, it remains a challenge for investigators to acquire the skills to take advantage of
these technologies. By combining the expertise of Cell P&P and Tool Cores, we will be able to efficiently
develop and deliver user-directed products to those investigators who may not otherwise be able to develop
these products within their labs. Through these deliverables, we will broaden the research potential for these
investigators and provide a mechanism to increase hematology research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
-
批准号:9899941
-
项目类别:
-
资助金额:$46.78万
-
财政年份:2016
-
负责人:DEREK L STIREWALT
-
依托单位:
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
-
批准号:9105139
-
项目类别:
-
资助金额:$57.62万
-
财政年份:2016
-
负责人:DEREK L STIREWALT
-
依托单位:
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
-
批准号:9452035
-
项目类别:
-
资助金额:$58.03万
-
财政年份:2016
-
负责人:DEREK L STIREWALT
-
依托单位:
Cell Procurement & Processing
-
批准号:10207253
-
项目类别:
-
资助金额:$15.42万
-
财政年份:2015
-
负责人:DEREK L STIREWALT
-
依托单位:
Stem Cell and Transplantation Biology
-
批准号:10472478
-
项目类别:
-
资助金额:$63.28万
-
财政年份:2015
-
负责人:DEREK L STIREWALT
-
依托单位:
Stem Cell and Transplantation Biology
-
批准号:10675711
-
项目类别:
-
资助金额:$63.28万
-
财政年份:2015
-
负责人:DEREK L STIREWALT
-
依托单位:
Cell Procurement & Processing
-
批准号:10675715
-
项目类别:
-
资助金额:$22.96万
-
财政年份:2015
-
负责人:DEREK L STIREWALT
-
依托单位:
Cell Procurement & Processing
-
批准号:10595863
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2015
-
负责人:DEREK L STIREWALT
-
依托单位:
Discovery and Optimization of AML Prognostic Biomarkers
-
批准号:8625275
-
项目类别:
-
资助金额:$47.04万
-
财政年份:2012
-
负责人:DEREK L STIREWALT
-
依托单位:
Discovery and Optimization of AML Prognostic Biomarkers
-
批准号:9024460
-
项目类别:
-
资助金额:$45.88万
-
财政年份:2012
-
负责人:DEREK L STIREWALT
-
依托单位:
Discovery and Optimization of AML Prognostic Biomarkers
-
批准号:8464673
-
项目类别:
-
资助金额:$47.06万
-
财政年份:2012
-
负责人:DEREK L STIREWALT
-
依托单位:
Discovery and Optimization of AML Prognostic Biomarkers
-
批准号:8296160
-
项目类别:
-
资助金额:$59.73万
-
财政年份:2012
-
负责人:DEREK L STIREWALT
-
依托单位:
IRF8 as a Biomarker of Aging, Malignant Transformation, and AML Prognosis
-
批准号:8006437
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2009
-
负责人:DEREK L STIREWALT
-
依托单位:
IRF8 as a Biomarker of Aging, Malignant Transformation, and AML Prognosis
-
批准号:7788239
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2009
-
负责人:DEREK L STIREWALT
-
依托单位:
Quantitative RT/PCR-based radiation dosimetry
-
批准号:7055179
-
项目类别:
-
资助金额:$43.63万
-
财政年份:2005
-
负责人:DEREK L STIREWALT
-
依托单位:
Examination of FLT3 Mutations in Acute Myeloid Leukemia
-
批准号:7074584
-
项目类别:
-
资助金额:$10.67万
-
财政年份:2002
-
负责人:DEREK L STIREWALT
-
依托单位:
Examination of FLT3 Mutations in Acute Myeloid Leukemia
-
批准号:6605868
-
项目类别:
-
资助金额:$13.37万
-
财政年份:2002
-
负责人:DEREK L STIREWALT
-
依托单位:
Examination of FLT3 Mutations in Acute Myeloid Leukemia
-
批准号:6757981
-
项目类别:
-
资助金额:$13.37万
-
财政年份:2002
-
负责人:DEREK L STIREWALT
-
依托单位:
Examination of FLT3 Mutations in Acute Myeloid Leukemia
-
批准号:6472559
-
项目类别:
-
资助金额:$13.37万
-
财政年份:2002
-
负责人:DEREK L STIREWALT
-
依托单位:
Examination of FLT3 Mutations in Acute Myeloid Leukemia
-
批准号:6909895
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2002
-
负责人:DEREK L STIREWALT
-
依托单位:
海外基金